Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 1197 is a small (~22 nucleotide) non-coding RNA molecule found in humans, encoded by the MIR1197 gene. Like other microRNAs, it is transcribed as part of a longer precursor (pri-miRNA), processed in the nucleus by Drosha into a stem-loop pre-miRNA, then exported and cleaved by Dicer in the cytoplasm to yield the mature miRNA. The mature miR-1197 is incorporated into the RNA-induced silencing complex (RISC), which recognizes partially complementary sequences in mRNA targets, leading to translational repression or mRNA destabilization. miR-1197 has been implicated in cancer biology, specifically in the regulation of tumor cell proliferation and migration. Its expression levels have been associated with disease stage and prognosis in cancers such as non-small cell lung cancer and pancreatic ductal adenocarcinoma, suggesting utility as a biomarker. There are no known approved drugs directly targeting miR-1197, but miRNA pathways are an area of active research for novel therapeutic strategies[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 1197 (miR-1197 (MIR1197)).